Protagonist Therapeutics, Inc Investing Cash Flow
Protagonist Therapeutics, Inc (PTGX) reported Investing Cash Flow of $88.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$2.43M, a 104.43% decline year-over-year.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $90.89M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $48.81M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$58.55M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for fiscal 2025 was -$49.33M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for fiscal 2024 was -$299.48M.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for fiscal 2023 was -$39.26M, a 142.92% decline from fiscal 2022.
- Protagonist Therapeutics, Inc net cash provided by (used in) investing activities for fiscal 2022 was $91.47M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $88.46M 10-Q · filed 2026-08-05 | $137.28M derived: sum of 3 quarters · filed 2026-08-05 | $78.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $90.89M 10-Q · filed 2026-05-05 | $139.71M derived: sum of 2 quarters · filed 2026-05-05 | $81.15M derived: sum of 3 quarters · filed 2026-05-05 | $135.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $48.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$9.74M derived: sum of 2 quarters · filed 2026-02-25 | $45.07M derived: sum of 3 quarters · filed 2026-08-05 | -$49.33M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$58.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.75M derived: sum of 2 quarters · filed 2026-08-05 | -$98.15M 10-Q · filed 2025-11-06 | -$106.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $54.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$39.59M 10-Q · filed 2026-08-05 | -$48.32M derived: sum of 3 quarters · filed 2026-08-05 | -$257.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$94.40M 10-Q · filed 2026-05-05 | -$103.13M derived: sum of 2 quarters · filed 2026-05-05 | -$311.84M derived: sum of 3 quarters · filed 2026-05-05 | -$399.96M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$217.44M derived: sum of 2 quarters · filed 2026-02-25 | -$305.55M derived: sum of 3 quarters · filed 2026-02-25 | -$299.48M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$208.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$296.83M derived: sum of 2 quarters · filed 2025-11-06 | -$290.76M 10-Q · filed 2025-11-06 | -$352.05M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$88.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$82.05M 10-Q · filed 2025-08-06 | -$143.34M derived: sum of 3 quarters · filed 2026-02-25 | -$156.89M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $6.07M 10-Q · filed 2025-05-06 | -$55.22M derived: sum of 2 quarters · filed 2026-02-25 | -$68.78M derived: sum of 3 quarters · filed 2026-02-25 | -$43.01M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$61.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$74.85M derived: sum of 2 quarters · filed 2026-02-25 | -$49.08M derived: sum of 3 quarters · filed 2026-02-25 | -$39.26M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$13.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $12.20M derived: sum of 2 quarters · filed 2024-11-07 | $22.03M 10-Q · filed 2024-11-07 | $25.96M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $25.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $35.59M 10-Q · filed 2024-08-06 | $39.52M derived: sum of 3 quarters · filed 2025-02-21 | $96.80M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $9.83M 10-Q · filed 2024-05-07 | $13.76M derived: sum of 2 quarters · filed 2025-02-21 | $71.04M derived: sum of 3 quarters · filed 2025-02-21 | $105.77M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $61.21M derived: sum of 2 quarters · filed 2025-02-21 | $95.94M derived: sum of 3 quarters · filed 2025-02-21 | $91.47M 10-K · filed 2025-02-21 |
| 2022-09-30 | $57.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $92.01M derived: sum of 2 quarters · filed 2023-11-02 | $87.53M 10-Q · filed 2023-11-02 | $115.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $34.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $30.26M 10-Q · filed 2023-08-03 | $58.13M derived: sum of 3 quarters · filed 2024-02-27 | $13.42M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$4.48M 10-Q · filed 2023-05-04 | $23.39M derived: sum of 2 quarters · filed 2024-02-27 | -$21.32M derived: sum of 3 quarters · filed 2024-02-27 | -$13.54M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $27.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$16.84M derived: sum of 2 quarters · filed 2024-02-27 | -$9.07M derived: sum of 3 quarters · filed 2024-02-27 | -$15.86M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$44.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$36.93M derived: sum of 2 quarters · filed 2022-11-08 | -$43.73M 10-Q · filed 2022-11-08 | -$118.13M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $7.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $980.00K 10-Q · filed 2022-08-04 | -$73.42M derived: sum of 3 quarters · filed 2023-03-15 | -$127.54M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$6.79M 10-Q · filed 2022-05-05 | -$81.19M derived: sum of 2 quarters · filed 2023-03-15 | -$135.32M derived: sum of 3 quarters · filed 2023-03-15 | -$140.49M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$74.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$128.52M derived: sum of 2 quarters · filed 2023-03-15 | -$133.69M derived: sum of 3 quarters · filed 2023-03-15 | -$90.97M 10-K · filed 2023-03-15 |
| 2020-09-30 | -$54.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$59.29M derived: sum of 2 quarters · filed 2021-11-03 | -$16.56M 10-Q · filed 2021-11-03 | -$29.12M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$5.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $37.56M 10-Q · filed 2021-08-04 | $25.00M derived: sum of 3 quarters · filed 2022-02-28 | -$7.03M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $42.73M 10-Q · filed 2021-05-04 | $30.18M derived: sum of 2 quarters · filed 2022-02-28 | -$1.86M derived: sum of 3 quarters · filed 2022-02-28 | -$15.09M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$12.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$44.59M derived: sum of 2 quarters · filed 2022-02-28 | -$57.82M derived: sum of 3 quarters · filed 2022-02-28 | -$53.71M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$32.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$45.26M derived: sum of 2 quarters · filed 2020-11-04 | -$41.16M 10-Q · filed 2020-11-04 | -$36.61M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | -$13.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$9.12M 10-Q · filed 2020-08-06 | -$4.57M derived: sum of 3 quarters · filed 2021-03-10 | $5.35M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | $4.11M 10-Q · filed 2020-05-07 | $8.66M derived: sum of 2 quarters · filed 2021-03-10 | $18.57M derived: sum of 3 quarters · filed 2021-03-10 | $28.16M derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $14.47M derived: sum of 2 quarters · filed 2021-03-10 | $24.06M derived: sum of 3 quarters · filed 2021-03-10 | $2.21M 10-K · filed 2021-03-10 |
| 2018-09-30 | $9.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $19.51M derived: sum of 2 quarters · filed 2019-11-06 | -$2.34M 10-Q · filed 2019-11-06 | $2.42M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $9.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$12.25M 10-Q · filed 2019-08-07 | -$7.50M derived: sum of 3 quarters · filed 2020-03-10 | -$8.27M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | -$21.84M 10-Q · filed 2019-05-08 | -$17.09M derived: sum of 2 quarters · filed 2020-03-10 | -$17.86M derived: sum of 3 quarters · filed 2020-03-10 | -$4.77M derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $3.98M derived: sum of 2 quarters · filed 2020-03-10 | $17.07M derived: sum of 3 quarters · filed 2020-03-10 | $15.82M 10-K · filed 2020-03-10 |
| 2017-09-30 | -$772.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $12.32M derived: sum of 2 quarters · filed 2018-11-06 | $11.07M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $13.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $11.84M 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | -$1.25M 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | -$59.33M 10-K · filed 2019-03-12 | |||
| 2015-12-31 | -$8.26M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |